Lv5
1336 积分 2024-04-01 加入
Impact of consolidation immunotherapy after definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: a real-world multicenter study
16天前
已完结
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
17天前
已完结
Iparomlimab and Tuvonralimab: First Approval
28天前
已完结
Induction chemotherapy plus PD-1 blockade and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: a propensity-matched retrospective study
1个月前
已关闭
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
1个月前
已完结
Tumor Immunity and Immunotherapy for HPV-Related Cancers
1个月前
已完结
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
1个月前
已完结
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
1个月前
已完结
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
1个月前
已完结
Dosimetric advantages of a novel X-Ray/γ-Ray integrated radiotherapy platform in cervical carcinoma: A comparative treatment planning study
1个月前
已完结
皖公网安备34019202002308
